🇺🇸 FDA
Pipeline program

Tolvaptan

156-12-204

Phase 3 small_molecule active

Quick answer

Tolvaptan for Autosomal Recessive Polycystic Kidney Disease is a Phase 3 program (small_molecule) at Otsuka Novel Products GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Otsuka Novel Products GmbH
Indication
Autosomal Recessive Polycystic Kidney Disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials